EsoCap has announced that scientists from the University of Greifswald published exciting data demonstrating that a novel drug delivery technology enables targeted and long-lasting local therapy of the esophagus for…
EsoCap AG announced today that the Japanese Patent and Trademark Office issued a patent under number 6719471 on June 18, 2020, based on international patent PCT/EP2015/002601. The patent is directed…
EsoCap has announced that Dr Jacques Gonella has been appointed to the Company’s Board of Directors. “I am delighted to welcome Jacques Gonella to the EsoCap Board,” said Dr Werner…
EsoCap AG has been recognised by Pharma Tech Outlook as a top drug discovery and development solution provider in Europe for 2020. “We are extremely pleased to have been chosen…
EsoCap AG announced today that the Russia Patent and Trademark Office issued a patent under number 2714882 on February 20, 2020, based on patent application no. 2017132866/04(057778). The patent is…
EsoCap has been selected as a finalist to present at the RESI Europe 2020 Innovation Challenge from 200+ companies. The RESI (Redefining Early Stage Investment) conference series was created to…
EsoCap AG announced today that its application device is ready to be used in clinical studies, as it is CE certified, after meeting Swiss and EU requirements under the European…
EsoCap AG announced presentation of new data, with smart application technology in the upper gastrointestinal tract demonstrating that long-lasting topical drug therapy within the esophagus is achievable for the first…
EsoCap AG has received Orphan Drug Designation from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE (eosinophilic esophagitis). “We are pleased…
EsoCap AG organized a multidisciplinary scientific advisory board meeting in Zurich with thirteen international experts on June 27, 2019. As an introduction, Prof. Werner Weitschies, Center for Drug Absorption and…
Malzgasse 9, CH-4052 Basel
